SynthesisArchives of dermatological research2025
Topical metformin in wound healing: a comprehensive systematic review of therapeutic outcomes.
Synthesis in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metformin as an Adjunct in Periodontal Therapy: Mechanistic Insights, Research Evidence and Current Challenges.Therapeutic innovation & regulatory science · 2026Review
- Phosphatidylserine liposomes containing metformin mitigate experimental atopic dermatitis: evidence for Akt/mTOR pathway involvement.Inflammopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metformin's topical application has proven to be a therapeutic wound healing dressing via pro-angiogenic, anti-inflammatory, autophagy-promoting, and antibacterial effects. The systematic review article aimed to evaluate the available evidence (from both preclinical and clinical studies), in order to better understand its therapeutic potential in wound care. We performed a systematic literature search in PubMed, Scopus, Web of Science, Embase, and Cochrane databases till January 2025. A total of 26 studies included in final analysis according to inclusion criteria. The majority of preclinical investigations demonstrated accelerated wound healing with characterized of increased wound closure and collagen deposition, elevated pro-angiogenic markers (e.g., VEGF, CD31, and α-SMA), suppression of pro-inflammatory cytokines, and induction of autophagy signaling. Notably, biomaterial-based delivery platform applications such as hydrogels and nanofibers greatly magnified these therapeutic effects. While encouraging results in in-vitro, in-vivo and animal models have been documented, clinical studies remain limited in scope. In fact, this large disparity between preclinical results and limited clinical evidences obviously highlights the urgent need for properly designed human trials to determine safety, efficacy, and best delivery modalities of topical metformin. Collectively, topical metformin is a novel and potentially valuable addition to wound treatment cares, which could be subjected to further clinical study.
Indexed as
Identifiers
40377758What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.